CIBC Bancorp USA
DNLI icon

CIBC Bancorp USA’s Denali Therapeutics DNLI Stock Holding History

CIBC Bancorp USA’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$301K Buy
14,543
+6,421
+79% +$150K ﹤0.01% 1682
2026
Q2 		$209K Buy
+8,122
New +$167K ﹤0.01% 1760
2025
Q3 		$205K Buy
+14,118
New +$203K ﹤0.01% 1253

Other funds holding DNLI

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $36.7B AUM 6.83% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

CIBC Bancorp USA's DNLI Position: Q3 2026 in Review

CIBC Bancorp USA increased its Denali Therapeutics (DNLI) stake by 79% in Q3 2026, buying an estimated $150K and bringing the position to 14,543 shares worth $301K. The position accounts for ﹤0.01% of the portfolio, ranked #1682.

CIBC Bancorp USA first reported a position in DNLI in Q3 2025 and has held it in 3 quarters since. 217 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

  • CIBC Bancorp USA held 14,543 shares of Denali Therapeutics worth $301K as of Q3 2026.
  • CIBC Bancorp USA bought 6,421 Denali Therapeutics shares in Q3 2026, an estimated $150K.
  • Denali Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #1682 holding.
  • CIBC Bancorp USA first reported a position in Denali Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 217 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.